Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Sionna Therapeutics director-affiliated entity records stock sales linked to OrbiMed funds. An investment vehicle, OrbiMed Private Investments VIII, LP, associated with reporting person Peter A. Thompson and OrbiMed Advisors, sold 1,890 shares of Sionna Therapeutics common stock at $44.57 on February 2, 2026.
The same entity sold an additional 29,063 shares at $44.58 on February 3, 2026, leaving 3,530,702 shares of Sionna common stock indirectly beneficially owned after the transactions. The filing notes that the reporting person and related OrbiMed entities disclaim beneficial ownership except to the extent of any pecuniary interest.
OrbiMed-related entities reported insider sales of Sionna Therapeutics common stock. On February 2, 2026, OrbiMed Private Investments VIII, LP sold 1,890 shares at $44.57 per share. On February 3, 2026, it sold an additional 29,063 shares at $44.58 per share.
After these transactions, 3,530,702 shares of Sionna common stock were reported as beneficially owned indirectly. The Form 4 was jointly filed by OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which may be deemed to share voting and investment power through their roles over OrbiMed Private Investments VIII, LP, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
TPG-affiliated investment entities that are 10% owners of Sionna Therapeutics, Inc. reported an indirect sale of 250,000 shares of common stock on January 22, 2026. The shares were sold at a price of $40 per share under transaction code "S," which indicates a sale.
After this transaction, entities associated with the reporting group indirectly held 6,494,962 shares of Sionna common stock through The Rise Fund Sling, L.P. and The Rise Fund Sling II, L.P. The filing explains that the reporting persons may be deemed to beneficially own these securities only to the extent of their direct or indirect pecuniary interests and they expressly disclaim beneficial ownership beyond those economic interests.
SION filed a Form 144 for a planned stock sale. A holder has notified the SEC of an intention to sell 195,667 shares of SION common stock, $0.001 par value per share, through Goldman Sachs & Co. LLC on or about 01/22/2026 on the Nasdaq Global Market. The filing lists an aggregate market value of $8,173,010.59 for these shares and notes that there were 44,628,788 shares of common stock outstanding at the time of the notice. The seller’s shares were originally acquired from the issuer on 02/10/2025 for cash and/or upon the automatic conversion of preferred stock into common stock.
SION filed a notice of proposed sale of restricted or control securities under Rule 144. The filing covers up to 54,333 shares of common stock, $0.001 par value per share, to be sold through Goldman Sachs & Co. LLC on the Nasdaq Global Market. The shares have an aggregate market value of $2,269,489.41 based on the filer’s calculation, and the planned sale date is listed as 01/22/2026.
The common stock to be sold was originally acquired on 02/10/2025 through the automatic conversion of preferred stock of the issuer into common stock, with 1,208,364 shares acquired in that conversion. The filing also notes that 44,628,788 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Sionna Therapeutics, Inc. reported that its Chief Medical Officer, Charlotte McKee, received a grant of a non-qualified stock option on January 2, 2026. The option covers 155,700 shares of common stock with an exercise price of $39.21 per share and an expiration date of January 1, 2036.
All 155,700 derivative securities are shown as beneficially owned directly following the transaction. According to the footnote, the shares underlying this option vest in 48 equal monthly installments after January 2, 2026, and each monthly vesting is conditioned on McKee’s continued service on the applicable vesting date.
Sionna Therapeutics Chief Business Officer Caroline Stark Beer was granted a non-qualified stock option for 139,340 shares of common stock. The option was awarded on January 2, 2026 with an exercise price of $39.21 per share. All 139,340 derivative securities are reported as directly owned following the transaction.
The shares underlying this option vest in forty-eight equal monthly installments after January 2, 2026, and each monthly vesting requires her continued service on that date. This filing reflects an equity compensation award rather than a sale of existing shares.
Sionna Therapeutics, Inc. (SION)11/20/2025 and 11/21/2025, these reporting persons sold multiple small blocks of Sionna common stock in open-market transactions.
The weighted average sale prices ranged from about $39.40 to $40.51 per share, with examples including 9,924 shares sold at a weighted average price of $39.50 and 801 shares sold at a weighted average price of $39.89. After these trades, the reported beneficial holdings for the various RA Capital funds and accounts remained large, such as 6,897,623 shares for one fund and over 2.1 million shares for another, as disclosed in the table.
Sionna Therapeutics (SION) reported insider activity on a Form 4 showing that RA Capital–affiliated entities, which are identified as both directors and 10% owners, sold shares of Sionna common stock over several days. On November 17, 2025, they executed multiple sales, including a sale of 17,913 shares of common stock at a weighted average price of
Additional sales took place on November 17–19, 2025 at weighted average prices described in the footnotes as ranging from
Sionna Therapeutics (SION) filed its Q3 2025 10‑Q, reporting a net loss of $20.3 million for the quarter and $54.8 million year-to-date as it advances cystic fibrosis programs. Cash, cash equivalents and marketable securities totaled $325.0 million as of September 30, 2025, supported by the February IPO.
Quarterly operating expenses were $23.8 million, including research and development $16.0 million and general and administrative $7.8 million. Interest income was $3.5 million. The company completed an IPO at $18.00 per share for net proceeds of approximately $199.6 million, and its preferred stock converted into 27,149,206 common shares. Shares outstanding were 44,628,788 as of October 31, 2025.
Sionna initiated a Phase 2a trial of SION‑719 as an add‑on to standard of care and a Phase 1 dual‑combination study with SION‑451, with topline data anticipated in mid‑2026. Management believes existing liquidity funds operations beyond twelve months and, based on current plans, into 2028.